OBJECTIVE In view of the emergence of non-albicans Candida and their resistance to available antifungals, an attempt has been made to develop novel effective agents. Biological activities of the N,N-dialkyl diosgenyl glycosides, which were previously synthesized, were determined. METHOD Minimum inhibitory concentration (MIC) was determined for group of clinical nonalbicans Candida isolates by serial
背景技术白色念珠菌属于人类中最常见的真菌病原体,但是最近已经报道了称为非白色念珠菌的菌株的增殖增加。属于这一类的物种通常以对抗真菌剂的敏感性降低为特征。目的鉴于非白色念珠菌的出现及其对可用抗真菌剂的耐药性,已尝试开发新型有效药剂。测定了先前合成的N,N-二烷基二
硫基糖苷的
生物活性。方法采用连续稀释法,在Sabouraud液体
培养基中测定临床非白色念珠菌分离株组的最低抑菌浓度(MIC)。为了评估对人细胞的毒性,在
磷酸缓冲液中通过系列稀释法确定了人红细胞上的最小溶血浓度(
MHC)。结果
皂甙对临床分离的光滑毛状线虫和副纤毛状线虫表现出很强的活性,与常规抗微
生物剂相比甚至更高。在光滑念珠菌分离物中显示出对
氟康唑的高耐药率。在克鲁氏梭菌和热带梭菌的临床菌株中,鉴定出对
皂苷敏感性降低的分离株。所有测试的克鲁斯克鲁维酵母分离株均显示出对
氟康唑的抗性,而在热带假丝酵母中,许多菌株对所有测试的唑类均具有抗性